000163024 001__ 163024
000163024 005__ 20240229123145.0
000163024 0247_ $$2doi$$a10.3238/arztebl.2020.0423
000163024 0247_ $$2pmid$$apmid:32885780
000163024 037__ $$aDKFZ-2020-01815
000163024 041__ $$aeng
000163024 082__ $$a610
000163024 1001_ $$0P:(DE-He78)39ab513728727300b8bd91be7120b69d$$aGruner, Laura$$b0$$eFirst author$$udkfz
000163024 245__ $$aThe Effects of Differing Invitation Models on the Uptake of Immunological Fecal Occult Blood Testing.
000163024 260__ $$aKöln$$bDt. Ärzte-Verl.$$c2020
000163024 3367_ $$2DRIVER$$aarticle
000163024 3367_ $$2DataCite$$aOutput Types/Journal article
000163024 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1603092435_18279
000163024 3367_ $$2BibTeX$$aARTICLE
000163024 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163024 3367_ $$00$$2EndNote$$aJournal Article
000163024 500__ $$a#EA:C070#LA:C070#
000163024 520__ $$aParticipation rates in colorectal cancer screening in Germany are low. We therefore investigated the effectiveness of different invitation models for immunological stool blood tests (fecal immunological tests, FITs).A randomized controlled trial in 50- to 54-year-old clients of the health insurance provider AOK Baden-Wuerttemberg. A total of 17 532 insured persons were randomized to receive: (A) an invitation letter including a FIT (n = 5850); (B) an invitation letter including an option to request a FIT (n = 5844); or (C) an invitation letter only (n = 5838; control group, routine practice). Reminder letters were sent to half the members of groups A and B, selected at random, after 4 weeks. The primary endpoint was the use of a FIT within 1 year of the date of the invitation letter. IRRID: RR2-10.2196/16413. Registration: DRKS00011858.The invitation letter with a FIT enclosed (A) increased usage from 10% to 29.7% compared with the control group (+19.7% points, p < 0.0001; men: +19.4%, women: +18.8%). The invitation letter with a FIT request option (B) increased usage from 10% to 27.7% (+17.7% points, p < 0.0001; men: +17.7%, women: +17.4%). Reminders increased usage in group A by 7.5% points and in group B by 8.5% points. Participation among women was higher than among men in all groups. The FIT positivity rate was 6.9%. A subsequent colonoscopy was reported for 64.3% of FIT-positive participants, and advanced neoplasia was found in 21.3% of these cases.Letters of invitation that include a FIT and those that offer low-threshold access to a FIT achieve strong, comparable increases in the usage of FIT in the context of colorectal cancer screening.
000163024 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000163024 588__ $$aDataset connected to CrossRef, PubMed,
000163024 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b1$$udkfz
000163024 7001_ $$aLudwig, Leopold$$b2
000163024 7001_ $$aMeny, Stefan$$b3
000163024 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4$$eLast author$$udkfz
000163024 773__ $$0PERI:(DE-600)2406159-1$$a10.3238/arztebl.2020.0423$$gVol. 117, no. 25$$n25$$p423-430$$tDeutsches Ärzteblatt international$$v117$$x1866-0452$$y2020
000163024 909CO $$ooai:inrepo02.dkfz.de:163024$$pVDB
000163024 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)39ab513728727300b8bd91be7120b69d$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000163024 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000163024 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000163024 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000163024 9141_ $$y2020
000163024 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bDTSCH ARZTEBL INT : 2018$$d2020-01-14
000163024 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-14
000163024 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-14
000163024 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-01-14
000163024 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-14
000163024 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-14
000163024 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-14
000163024 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-14
000163024 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-01-14
000163024 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000163024 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000163024 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000163024 980__ $$ajournal
000163024 980__ $$aVDB
000163024 980__ $$aI:(DE-He78)C070-20160331
000163024 980__ $$aI:(DE-He78)C120-20160331
000163024 980__ $$aI:(DE-He78)HD01-20160331
000163024 980__ $$aUNRESTRICTED